Yasir Mahmood

Yasir Mahmood

Auto-generated profile, based on publicly available information

Yasir Mahmood

Translational Oncology Program, Garvan Institute of Medical Research, Sydney, Australia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PBPatrick Bergsma
Patrick Bergsma
SPSean Porazinski
Sean Porazinski
AIAji Istadi
Aji Istadi
DCDiego Chacon-Fajardo
Diego Chacon-Fajardo
YMYasir Mahmood
Yasir Mahmood
MPMarina Pajic
Marina Pajic
Precision medicine is a likely future for all cancer treatment but may have its greatest impact on less common, high-mortality, and molecularly heterogeneous cancers. TFCP2-rearranged rhabdomyosarcoma (RMS) is a rare, aggressive cancer with poor survival due to the lack of effective therapies and relevant models to facilitate research. In this study, we establish the first matched patient-derived xenograft and cell line model for TFCP2-rearranged intraosseous RMS, coupled with comprehensive multiomic and functional analyses, to discover and preclinically validate novel actionable molecular targets for this malignancy. Sequencing analyses of matched patient tumor and xenograft material revealed alterations in gene networks associated with the oncogenic, potentially targetable PI3K/AKT pathway. Preclinical assessments revealed that targeting the pathway with a small-molecule PI3K/mTOR inhibitor dactolisib presents a promising treatment approach for this rare cancer, decreasing cancer cell viability in vitro and significantly reducing tumor growth in vivo. Parallel identification of the codeletion of adjacent genes cyclin-dependent kinase inhibitor 2A and methylthioadenosine phosphorylase in these tumors led us to further explore protein arginine methyltransferase 5 inhibition as a potential therapeutic approach. Strikingly, combined inhibition of protein arginine methyltransferase 5 and PI3K/mTOR signaling synergistically enhanced antitumor response and significantly improved survival in vivo. This study highlights the importance of new patient-derived models for the elucidation of the biology of rare cancers and identification of new therapeutic entry points, with clear implications for the future treatment of TFCP2-rearranged intraosseous RMS.

2 December 2025
Verified
Other
Open access
PBPatrick Bergsma
Patrick Bergsma
SPSean Porazinski
Sean Porazinski
AIAji Istadi
Aji Istadi
DCDiego Chacon-Fajardo
Diego Chacon-Fajardo
YMYasir Mahmood
Yasir Mahmood
MPMarina Pajic
Marina Pajic
Precision medicine is a likely future for all cancer treatment but may have its greatest impact on less common, high-mortality, and molecularly heterogeneous cancers. TFCP2-rearranged rhabdomyosarcoma (RMS) is a rare, aggressive cancer with poor survival due to the lack of effective therapies and relevant models to facilitate research. In this study, we establish the first matched patient-derived xenograft and cell line model for TFCP2-rearranged intraosseous RMS, coupled with comprehensive multiomic and functional analyses, to discover and preclinically validate novel actionable molecular targets for this malignancy. Sequencing analyses of matched patient tumor and xenograft material revealed alterations in gene networks associated with the oncogenic, potentially targetable PI3K/AKT pathway. Preclinical assessments revealed that targeting the pathway with a small-molecule PI3K/mTOR inhibitor dactolisib presents a promising treatment approach for this rare cancer, decreasing cancer cell viability in vitro and significantly reducing tumor growth in vivo. Parallel identification of the codeletion of adjacent genes cyclin-dependent kinase inhibitor 2A and methylthioadenosine phosphorylase in these tumors led us to further explore protein arginine methyltransferase 5 inhibition as a potential therapeutic approach. Strikingly, combined inhibition of protein arginine methyltransferase 5 and PI3K/mTOR signaling synergistically enhanced antitumor response and significantly improved survival in vivo. This study highlights the importance of new patient-derived models for the elucidation of the biology of rare cancers and identification of new therapeutic entry points, with clear implications for the future treatment of TFCP2-rearranged intraosseous RMS.

2 December 2025
Verified
Other
Open access
PBPatrick Bergsma
Patrick Bergsma
SPSean Porazinski
Sean Porazinski
AIAji Istadi
Aji Istadi
DCDiego Chacon-Fajardo
Diego Chacon-Fajardo
YMYasir Mahmood
Yasir Mahmood
MPMarina Pajic
Marina Pajic
Supplementary Fig. S2 shows additional genomic and transcriptomic profiling of IORMS, including FUS-TFCP2 fusion, copy number signature activity, overlap with MSK-IMPACT gene panel, and enriched pathways from differential expression analysis.

2 December 2025
Verified
Other
Open access
PBPatrick Bergsma
Patrick Bergsma
SPSean Porazinski
Sean Porazinski
AIAji Istadi
Aji Istadi
DCDiego Chacon-Fajardo
Diego Chacon-Fajardo
YMYasir Mahmood
Yasir Mahmood
MPMarina Pajic
Marina Pajic
Supplementary Table S7 shows the assessment of gene alterations in IORMS-01 and TKCC-IORMS-01 across actionable targets from the TSO500 and MSK-IMPACT panels.

2 December 2025
Verified
Other
Open access
PBPatrick Bergsma
Patrick Bergsma
SPSean Porazinski
Sean Porazinski
AIAji Istadi
Aji Istadi
DCDiego Chacon-Fajardo
Diego Chacon-Fajardo
YMYasir Mahmood
Yasir Mahmood
MPMarina Pajic
Marina Pajic
Supplementary Table S8 shows the normalized expression matrix of RNA-seq data from the IORMS-01 tumor in the context of RMS cases from Watson and colleagues, Journal of Pathology 2018.

2 December 2025
Verified
Other
Open access
PBPatrick Bergsma
Patrick Bergsma
SPSean Porazinski
Sean Porazinski
AIAji Istadi
Aji Istadi
DCDiego Chacon-Fajardo
Diego Chacon-Fajardo
YMYasir Mahmood
Yasir Mahmood
MPMarina Pajic
Marina Pajic
Supplementary Fig. S5 shows additikonal molecular analysis of tumors from the in vivo treatment study for LLY-283, dactolisib and the combination of LLY-283 and dactolisib, including IHC for CC3, HIF1α, p-H2AX, αSMA, and Picrosirius Red staining with birefringence imaging to assess ECM remodelling.